Tribute Pharmaceuticals Canada Inc.
|
(Name of Issuer) |
Common Shares, no par value
|
(Title of Class of Securities) |
89609J106
|
(CUSIP Number) |
Robert Harris
151 Steeles Avenue, East
Milton, Ontario, Canada L9T 1Y1
(519) 434-1540
|
(Name, address and telephone number of person
authorized to receive notices and communications)
|
December 1, 2011
|
(Date of event which requires filing of this statement) |
CUSIP No. 89609J106 | SCHEDULE 13D | Page 2 of 6 Pages |
1
|
NAME OF REPORTING PERSONS
Robert Paul Harris
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Not Applicable
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
|
|||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
PF, OO
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Canada
|
|||
NUMBER OF
|
7
|
SOLE VOTING POWER
|
6,160,650
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING POWER
|
4,125,000
|
|
OWNED BY
EACH
|
9
|
SOLE DISPOSITIVE POWER
|
6,160,650
|
|
REPORTING
PERSON WITH
|
10
|
SHARED DISPOSITIVE POWER
|
4,125,000
|
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,285,650
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES þ
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.3% (99,088,738 common shares of the Company were issued and outstanding as of February 26, 2015)
|
|||
14
|
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 89609J106 | SCHEDULE 13D | Page 3 of 6 Pages |
|
(b)
|
The address of Mr. Harris is c/o Tribute Pharmaceuticals Canada Inc., 151 Steeles Avenue, East, Milton, Ontario, Canada L9T 1Y1
|
|
(c)
|
Mr. Harris is the President, Chief Executive Officer and a director of the Company.
|
|
(d)
|
Mr. Harris has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
|
|
(e)
|
Mr. Harris has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, nor, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or maintaining activities subject to, federal or state securities laws or finding any violation with respect to such laws.
|
CUSIP No. 89609J106 | SCHEDULE 13D | Page 4 of 6 Pages |
|
(a)
|
Mr. Harris is the beneficial owner of 10,285,650 common shares, or 10.3% of the Company’s outstanding common shares as of February 26, 2015, which includes (i) 5,062,500 common shares held by Mr. Harris, (ii) 4,125,000 common shares held by Mr. Harris' spouse, (iii) 730,457 common shares issuable pursuant to options granted under the Company’s stock option plan that are vested and exercisable within 60 days after the date hereof at an exercise price of Cdn$0.57 per share; (iv) 52,500 common shares issuable pursuant to options granted under the Company’s stock option plan that are vested and exercisable within 60 days after the date hereof at an exercise price of Cdn$0.42 per share; (v) 2,693 common shares issuable pursuant to options granted under the Company’s stock option plan that are vested and exercisable within 60 days after the date hereof at an exercise price of Cdn$0.40 per share; and (vi) 312,500 common shares underlying Series B warrants, which are exercisable from February 27, 2013 until February 27, 2018 at an exercise price of Cdn$0.60 per share, subject to a certain right of the Company to call the Series B warrants.
|
|
(b)
|
Number of shares as to which such person has:
|
|
(i)
|
Sole power to vote or to direct the vote: 6,160,650 common shares of the Company.
|
|
(ii)
|
Shared power to vote or to direct the vote: 4,125,000 common shares of the Company.
|
|
(iii)
|
Sole power to dispose or to direct the disposition: 6,160,650 common shares of the Company.
|
|
(iv)
|
Shared power to dispose or to direct the disposition: 4,125,000 common shares of the Company.
|
|
(c)
|
On February 19, 2015, the Company issued 312,500 common shares to Mr. Harris, for aggregate cash consideration of US$156,250, as a result of certain exercises of Series A Warrants. Other than the foregoing, Mr. Harris did not effect any transactions in the Company’s common shares during the sixty (60) days preceding the date of this Schedule 13D.
|
|
(d)
|
Not applicable.
|
|
(e)
|
Not applicable.
|
CUSIP No. 89609J106 | SCHEDULE 13D | Page 5 of 6 Pages |
1. | Share Purchase Agreement dated December 1, 2011 between the Company, Elora Financial Management Inc., Mary-Ann Harris, Robert Harris and Scott Langille (incorporated by reference from Exhibit 2.1 to the Form 8-K/A filed by the Issuer with the Commission on February 11, 2013). | |
2. | Employment Agreement between the Company and Mr. Harris dated December 1, 2011 (incorporated by reference from Exhibit 10.1 to the Form 8-K/A filed by the Issuer with the Commission on February 11, 2013). | |
3. | Securities Purchase Agreement dated February 27, 2013 (incorporated by reference from Exhibit 10.1 to the Form 8-K filed by the Issuer with the Commission on March 5, 2013). | |
4. | Registration Rights Agreement dated February 27, 2013 (incorporated by reference from Exhibit 10.2 to the Form 8-K filed by the Issuer with the Commission on March 5, 2013). | |
5. | Form of Series A/Series B warrant (incorporated by reference from Exhibit 10.3 to the Form 8-K filed by the Issuer with the Commission on March 5, 2013). | |
6. | Amending Agreement dated February 6, 2014 between the Company and Mr. Harris. | |
7. | Employment Agreement between the Company and Mr. Harris dated January 1, 2015 (incorporated by reference from Exhibit 10.1 to the Form 8-K filed by the Issuer with the Commission on February 2, 2015). |
Date: March 18, 2015
|
By:
|
/s/ Robert Harris | |
Robert Harris
|
|||